Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

OBJECTIVE. Somatic HER2 mutations occur in ~5% of cervical cancers and are considered oncogenic and associated with poor prognosis. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is active in multiple HER2-mutant cancers. SUMMIT is a phase II basket trial investigating the efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Oaknin, Ana, Friedman, Claire F., Roman, Lynda D., D’Souza, Anishka, Brana, Irene, Bidard, François-Clement, Goldman, Jonathan, Alvarez, Edwin A., Boni, Valentina, ElNaggar, Adam C., Passalacqua, Rodolfo, Do, Khanh T.M., Santin, Alessandro D., Keyvanjah, Kiana, Xu, Feng, Eli, Lisa D., Lalani, Alshad S., Bryce, Richard P., Hyman, David M., Meric-Bernstam, Funda, Solit, David B., Monk, Bradley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336424/
https://www.ncbi.nlm.nih.gov/pubmed/32723675
http://dx.doi.org/10.1016/j.ygyno.2020.07.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336424/
https://www.ncbi.nlm.nih.gov/pubmed/32723675
http://dx.doi.org/10.1016/j.ygyno.2020.07.025

Ejemplares similares